Bruce Coate
Acadia Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Parkinson's Disease Mechanisms and Treatments, Attention Deficit Hyperactivity Disorder, Cholinesterase and Neurodegenerative Diseases, HIV/AIDS drug development and treatment, Alzheimer's disease research and treatments
Most-Cited Works
- → Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study(2018)187 cited
- → Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis(2015)56 cited
- → Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications(2018)55 cited
- → Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily(2013)50 cited
- → Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms(2019)39 cited
- → Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial(2012)30 cited
- → Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial(2013)26 cited
- → Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson’s Disease Psychosis(2018)25 cited
- → An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression(2020)23 cited
- → Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients(2021)22 cited